Skip to content

Donepezil Hydrochloride

FDA-approved product (tablet, oral), marketed as Adlarity, Aricept, Aricept Odt and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Donepezil Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Alzheimer disease
  • Dementia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anticholinesterases
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA44.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Donepezil Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties

    NCT00315367 · start 2004-09

    Registered record
    Registry ID
    NCT00315367
    Conditions
    Relapsing-Remitting Multiple Sclerosis
    Interventions
    Donepezil HCI (drug)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-09
    Completion
    2007-10
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsing-Remitting Multiple Sclerosis
    InterventionDonepezil HCI (drug)
    PhasePhase 4
    Registry statusCompleted
  • An Evaluation Of The Efficacy And Safety Of Donepezil Hydrochloride (E2020) In Migraine Prophylaxis

    NCT01146509 · start 2003-01

    Registered record
    Registry ID
    NCT01146509
    Conditions
    Migraine Headache
    Interventions
    Aricept (donepezil hydrochloride)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-01
    Completion
    2007-03
    Enrolment
    89

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Headache
    InterventionAricept (donepezil hydrochloride)
    PhasePhase 2
    Registry statusCompleted
  • The CAMPUS Project: Cholinergic Augmentation of Cognitive Deficits in Schizophrenia

    NCT00206947 · start 2002-12

    Registered record
    Registry ID
    NCT00206947
    Conditions
    Schizophrenia
    Interventions
    donepezil (5-10 mg/day); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2002-12
    Completion
    2005-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventiondonepezil (5-10 mg/day); Placebo
    PhasePhase 2
    Registry statusTerminated
  • Donepezil to Treat Dementia in Parkinson's Disease

    NCT00030979 · start 2002-02

    Registered record
    Registry ID
    NCT00030979
    Conditions
    Parkinson Disease
    Interventions
    Donepezil
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-02
    Completion
    2005-03
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionDonepezil
    PhasePhase 4
    Registry statusCompleted
  • Tiagabine, Sertraline, or Donepezil for the Treatment of Cocaine Dependence - 9

    NCT00015132 · start 1999-03

    Registered record
    Registry ID
    NCT00015132
    Conditions
    Cocaine-Related Disorders
    Interventions
    Sertraline
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1999-03
    Completion
    2000-11
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCocaine-Related Disorders
    InterventionSertraline
    PhasePhase 2
    Registry statusCompleted